Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DTYMK | P23919 | 2/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21539898 | 0.91 | ALDH1A1 (0.51) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL21539867 | 0.91 | ALDH1A1 (0.51) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL21540035 | 0.91 | ALDH1A1 (0.51) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL21636993 | 0.89 | ALDH1A1 (0.48) | ALDH1A1LMNAALBMAPK1DTYMK | |
| SCHEMBL21540016 | 0.86 | ALDH1A1 (0.51) | ALDH1A1LMNAALBMAPK1DTYMK | |
| SCHEMBL21539917 | 0.86 | ALDH1A1 (0.51) | ALDH1A1LMNAALBMAPK1DTYMK | |
| SCHEMBL21539922 | 0.85 | ALDH1A1 (0.57) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL25582525 | 0.84 | RNASEL (0.57) | POLBRNASEL | |
| SCHEMBL21539899 | 0.84 | ALDH1A1 (0.49) | ALDH1A1LMNAALBMAPK1DTYMK | |
| SCHEMBL20325281 | 0.84 | ALDH1A1 (0.46) | ALDH1A1LMNAALBMAPK1RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233882-B1 | FLUORINATED CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2019-10-30 | — | — | EP | disclosed |